Log in
NYSE:NVRO

Nevro Stock Forecast, Price & News

$162.27
+6.27 (+4.02 %)
(As of 10/22/2020 12:00 AM ET)
Add
Compare
Today's Range
$156.57
Now: $162.27▼
$166.29
50-Day Range
$134.73
MA: $143.20▼
$156.00
52-Week Range
$65.05
Now: $162.27▼
$166.29
Volume494,939 shs
Average Volume412,152 shs
Market Capitalization$5.57 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.86
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. It also offers Senza II system and Senza Omnia system products for chronic pain. The company's solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. Nevro Corp. sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was founded in 2006 and is headquartered in Redwood City, California.
Read More
Nevro logo

Beat the Market (BTM) Rank™

Analyst Opinion: 2.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.20 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:NVRO
Previous Symbol
CUSIPN/A
CIK1444380
Webwww.nevro.com
Phone650-251-0005
Employees853

Debt

Debt-to-Equity Ratio0.37
Current Ratio3.25
Quick Ratio2.83

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$390.26 million
Price / Sales14.27
Cash FlowN/A
Price / Cash FlowN/A
Book Value$6.98 per share
Price / Book23.25

Profitability

EPS (Most Recent Fiscal Year)($3.37)
Net Income$-103,690,000.00
Net Margins-27.22%
Return on Equity-38.86%
Return on Assets-18.31%

Miscellaneous

Outstanding Shares34,313,000
Market Cap$5.57 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$162.27
+6.27 (+4.02 %)
(As of 10/22/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVRO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVRO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Nevro (NYSE:NVRO) Frequently Asked Questions

How has Nevro's stock been impacted by Coronavirus (COVID-19)?

Nevro's stock was trading at $109.82 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NVRO shares have increased by 47.8% and is now trading at $162.27.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Nevro?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Nevro.

When is Nevro's next earnings date?

Nevro is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Nevro.

How were Nevro's earnings last quarter?

Nevro Corp. (NYSE:NVRO) issued its quarterly earnings data on Wednesday, August, 5th. The medical equipment provider reported ($1.21) earnings per share for the quarter, topping analysts' consensus estimates of ($1.65) by $0.44. The medical equipment provider earned $56.39 million during the quarter, compared to the consensus estimate of $41.46 million. Nevro had a negative net margin of 27.22% and a negative return on equity of 38.86%.
View Nevro's earnings history.

What price target have analysts set for NVRO?

13 Wall Street analysts have issued 1 year target prices for Nevro's shares. Their forecasts range from $100.00 to $175.00. On average, they expect Nevro's stock price to reach $143.09 in the next twelve months. This suggests that the stock has a possible downside of 11.8%.
View analysts' price targets for Nevro.

Who are some of Nevro's key competitors?

Some companies that are related to Nevro include Teleflex (TFX), Insulet (PODD), Novocure (NVCR), ABIOMED (ABMD), Penumbra (PEN), Tandem Diabetes Care (TNDM), Irhythm Technologies (IRTC), Hill-Rom (HRC), Haemonetics (HAE), Globus Medical (GMED), Integra LifeSciences (IART), ICU Medical (ICUI), Inspire Medical Systems (INSP), Inari Medical (NARI) and Merit Medical Systems (MMSI).
View all competitors.

What other stocks do shareholders of Nevro own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), The Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG).

Who are Nevro's key executives?

Nevro's management team includes the following people:
  • Mr. D. Keith Grossman, Chairman, CEO & Pres (Age 60, Pay $1.6M)
  • Mr. Kashif Rashid, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 46, Pay $705.96k)
  • Mr. Michael Collier Carter, VP of Global Sales (Age 48, Pay $841.82k)
  • Mr. Andrew H. Galligan, Exec. Officer (Age 64, Pay $812.72k)
  • Ms. Niamh Louise Pellegrini, Chief Commercial Officer (Age 53, Pay $853.27k)

What is Nevro's stock symbol?

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Who are Nevro's major shareholders?

Nevro's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.04%), FNY Investment Advisers LLC (0.03%) and Nisa Investment Advisors LLC (0.00%). Company insiders that own Nevro stock include Andrew H Galligan, Doug Alleavitch, Elizabeth H Weatherman, Kevin C Oboyle, Michael F Demane, Niamh Louise Pellegrini and Shawn Mccormick.
View institutional ownership trends for Nevro.

Which major investors are buying Nevro stock?

NVRO stock was bought by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC, Nisa Investment Advisors LLC, and Envestnet Asset Management Inc.. Company insiders that have bought Nevro stock in the last two years include Elizabeth H Weatherman, and Kevin C Oboyle.
View insider buying and selling activity for Nevro.

How do I buy shares of Nevro?

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Nevro's stock price today?

One share of NVRO stock can currently be purchased for approximately $162.27.

How big of a company is Nevro?

Nevro has a market capitalization of $5.57 billion and generates $390.26 million in revenue each year. The medical equipment provider earns $-103,690,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Nevro employs 853 workers across the globe.

What is Nevro's official website?

The official website for Nevro is www.nevro.com.

How can I contact Nevro?

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]

This page was last updated on 10/23/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.